bms-986368

BMS-986368 (also known as CC-97489) is an orally administered small molecule drug in clinical development for neurological disorders. It is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL), enzymes involved in the degradation of endocannabinoids. By inhibiting both FAAH and MGLL, BMS-986368 increases levels of endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol, which may provide neuroprotective effects and modulate neurotransmission relevant to conditions like epilepsy, multiple sclerosis spasticity, agitation in Alzheimer's disease, and other neurodegenerative diseases. The drug was originally developed by Celgene and is now being developed by Bristol Myers Squibb following their acquisition of Celgene[1][3][4][5][6].

Other names

FAAH/MGLL dual inhibitor